RNIN - ETF AI Analysis

Top Page

Bushido Capital US SMID Cap Equity ETF (RNIN)

Rating:69Neutral

Price Target:―

The ETF RNIN, Bushido Capital US SMID Cap Equity ETF, has a moderate overall rating, driven by a mix of strong and weaker holdings. Collegium Pharmaceutical stands out as a key contributor, with its strong financial performance and strategic growth focus supporting the fund's rating. On the other hand, holdings like Cormedix and World Kinect have faced challenges in profitability and operational efficiency, which may have weighed on the ETF's overall score. The fund's diverse holdings help balance risks, but its exposure to companies with financial or operational challenges could pose some risk to investors.

Positive Factors

Strong Sector Diversification

The ETF is spread across multiple sectors, with notable exposure to Consumer Cyclical, Energy, and Health Care, reducing reliance on any single industry.

Healthy Year-to-Date Performance

The fund has delivered strong year-to-date returns, indicating positive momentum in its portfolio.

Exposure to Smaller Companies

The focus on small and mid-cap companies provides growth potential that may outperform larger, more established firms over time.

Negative Factors

High Geographic Concentration

The ETF is almost entirely focused on U.S. companies, limiting diversification across global markets.

Mixed Performance Among Top Holdings

Several top holdings have underperformed year-to-date, which could drag on overall returns.

Relatively High Expense Ratio

The fund's expense ratio is higher than many ETFs, which could eat into investor returns over time.

RNIN vs. SPDR S&P 500 ETF (SPY)

AUM130.54M

RegionNorth America

Expense Ratio0.68%

Beta0.96

IssuerBushido

Inception DateMay 14, 2025

Dividend YieldN/A

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume5,178

30 Day Avg. Volume4,569

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

33.70

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering81

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

RNIN Summary

The Bushido Capital US SMID Cap Equity ETF (Ticker: RNIN) is an actively managed fund that focuses on small- and mid-sized companies in the United States. It aims to find undervalued businesses with strong growth potential, offering a mix of industries like consumer goods, energy, healthcare, and technology. Some of its holdings include Crocs and Gulfport Energy, giving investors exposure to unique and growing sectors. This ETF could be a good choice for those looking to diversify beyond large-cap stocks and tap into emerging opportunities. However, it’s important to note that small- and mid-cap stocks can be more volatile, meaning their prices may rise and fall more dramatically than larger companies.

How much will it cost me?The Bushido Capital US SMID Cap Equity ETF (Ticker: RNIN) has an expense ratio of 0.68%, which means you’ll pay $6.80 per year for every $1,000 invested. This is higher than average because the fund is actively managed, requiring more research and decision-making compared to passively managed ETFs that track an index.

What would affect this ETF?The Bushido Capital US SMID Cap Equity ETF (RNIN) could benefit from positive trends in sectors like Consumer Cyclical, Energy, and Technology, which are heavily weighted in its portfolio and may thrive during periods of economic growth or innovation. However, it may face challenges if interest rates rise, as smaller companies often have higher borrowing costs, or if economic conditions weaken, impacting consumer spending and energy demand. Its focus on U.S. small- and mid-cap stocks also makes it sensitive to domestic economic and regulatory changes.

RNIN Top 10 Holdings

The Bushido Capital US SMID Cap Equity ETF is leaning heavily into consumer cyclical and energy sectors, which together make up nearly half of its portfolio. Gulfport Energy is showing steady performance, buoyed by increased production, while Collegium Pharmaceutical is rising on bullish momentum and strategic growth initiatives. On the flip side, Ziff Davis and StubHub Holdings are lagging, with mixed financial results and bearish trends holding them back. With its focus on U.S. small- and mid-cap stocks, the fund offers concentrated exposure to high-potential sectors but faces challenges from a few underperforming names.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
CDE	Coeur Mining	1.72%	$2.27M	$16.51B	304.24%	69 Neutral
BG	Bunge Global	1.54%	$2.03M	$22.46B	48.49%	66 Neutral
CENX	Century Aluminum	1.52%	$2.01M	$4.46B	163.04%	61 Neutral
MOH	Molina Healthcare	1.48%	$1.94M	$9.46B	-39.49%	71 Outperform
BLDR	Builders Firstsource	1.47%	$1.94M	$12.97B	-30.44%	63 Neutral
ALKS	Alkermes	1.44%	$1.90M	$5.53B	6.21%	80 Outperform
STUB	StubHub Holdings Incorporation Class A	1.42%	$1.87M	$4.77B	―	59 Neutral
CF	Cf Industries Holdings	1.39%	$1.83M	$14.31B	0.70%	72 Outperform
ZD	Ziff Davis	1.39%	$1.83M	$1.56B	-26.71%	69 Neutral
WKC	World Kinect	1.39%	$1.83M	$1.45B	-9.12%	51 Neutral

RNIN Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

27.81

Positive

100DMA

27.46

Positive

200DMA

Market Momentum

MACD

0.15

Positive

RSI

53.64

Neutral

STOCH

61.24

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RNIN, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 28.19, equal to the 50-day MA of 27.81, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 53.64 is Neutral, neither overbought nor oversold. The STOCH value of 61.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RNIN.

RNIN Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
RNIN	―	―	$130.54M	0.68%	―
RSMC	―	―	$739.52M	0.75%	―
MSSM	―	―	$723.94M	0.57%	―
GRNJ	―	―	$345.59M	0.75%	―
NBSM	―	―	$211.61M	0.65%	―
SMIZ	―	―	$189.65M	0.56%	―

Performance Comparison

RNIN

Bushido Capital US SMID Cap Equity ETF

28.30

3.02

11.95%

RSMC

Rockefeller U.S. Small-Mid Cap ETF

―

MSSM

Morgan Stanley Pathway Small-Mid Cap Equity ETF

―

GRNJ

Fundstrat Granny Shots US Small- & Mid-Cap ETF

―

NBSM

Neuberger Berman Small-Mid Cap ETF

―

SMIZ

Zacks Small/Mid Cap ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents